Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinson's Disease Therapy

被引:219
|
作者
Woo, Seo Yeon [1 ]
Kim, Ji Hyun [3 ]
Moon, Mi Kyeong [3 ]
Han, Se-Hee [3 ]
Yeon, Seul Ki [1 ]
Choi, Ji Won [1 ]
Jang, Bo Ko [1 ]
Song, Hyo Jung [1 ]
Kang, Yong Gu [1 ]
Kim, Jin Woo [1 ]
Lee, Jaeick [2 ]
Kim, Dong Jin [1 ]
Hwang, Onyou [3 ]
Park, Ki Duk [1 ]
机构
[1] Brain Sci Inst, Ctr Neuromed, Seoul 136791, South Korea
[2] Korea Inst Sci & Technol, Doping Control Ctr, Seoul 136791, South Korea
[3] Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea
基金
新加坡国家研究基金会;
关键词
MPTP MOUSE MODEL; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; CHALCONE DERIVATIVES; SYNTHETIC CHALCONE; HEME OXYGENASE-1; POTENT INDUCER; NRF2; TETRAHYDROBIOPTERIN; CELLS;
D O I
10.1021/jm401788m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Although the etiology of Parkinson's disease (PD) remains elusive, recent studies suggest that oxidative stress contributes to the cascade leading to dopaminergic (DAergic) neurodegeneration. The Nrf2, signaling is the main pathway responsible for cellular defense system against oxidative stress. Nrf2 is a transcription factor that regulates environmental stress response by inducing expression of antioxidant enzyme genes. We have synthesized novel vinyl sulfone derivatives. They exhibited a broad range of activities in inducing HO-1, whose gene expression is under the control of Nrf2. Among them, compound 12g was confirmed to activate Nrf2 and induce expression of the Nrf2-dependent antioxidant enzymes NQO1, GCLC, GLCM, and HO-1, at both mRNA and protein levels in DAergic neuronal cells. This was accompanied by protection of DAergic neurons in both in vitro and MPTP-induced in vivo models of PD. In addition, compound 12g effectively resulted in attenuation of the PD-associated behavioral deficits in the mouse model.
引用
收藏
页码:1473 / 1487
页数:15
相关论文
共 50 条
  • [21] Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease
    Sanz, E
    Romera, M
    Belyk, L
    Marco, J
    Unzeta, M
    MEDICAL SCIENCE MONITOR, 2004, 10 (12): : BR477 - BR484
  • [22] Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease - Discussion
    Olanow
    Schapira
    Isacson
    Rascol
    Brooks
    Tatton
    Marek
    Beal
    Jenner
    Stocchi
    ANNALS OF NEUROLOGY, 2003, 53 : S157 - S159
  • [23] Plant-derived compounds as potential neuroprotective agents in Parkinson's disease
    Niu, Chengu
    Zou, Yu
    Dong, Miaoxian
    Niu, Yingcai
    NUTRITION, 2025, 130
  • [25] Trial Designs Used to Study Neuroprotective Therapy in Parkinson's Disease
    Lang, Anthony E.
    Melamed, Eldad
    Poewe, Werner
    Rascol, Olivier
    MOVEMENT DISORDERS, 2013, 28 (01) : 86 - 95
  • [26] Interest in predictive testing for Parkinson's disease:: Impact of neuroprotective therapy
    Dahodwala, N.
    Connolly, J.
    Farmer, J.
    Stern, M. B.
    Jennings, D.
    Siderowf, A.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 (08) : 495 - 499
  • [27] Neuroprotective effects of GLP-1 class drugs in Parkinson's disease
    Lv, Dongliang
    Feng, Peng
    Guan, Xueying
    Liu, Zhaona
    Li, Dongfang
    Xue, Cunshui
    Bai, Bo
    Holscher, Christian
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [28] Nanomaterials as novel agents for amelioration of Parkinson's disease
    Wu, Junguang
    Cui, Xuejing
    Ke, Pu Chun
    Mortimer, Monika
    Wang, Xiaoyu
    Bao, Lin
    Chen, Chunying
    NANO TODAY, 2021, 41
  • [29] Panax ginseng is neuroprotective in a novel progressive model of Parkinson's disease
    Van Kampen, Jackalina M.
    Baranowski, David B.
    Shaw, Christopher A.
    Kay, Denis G.
    EXPERIMENTAL GERONTOLOGY, 2014, 50 : 95 - 105
  • [30] Neuroprotective Treatments in Parkinson's Disease
    Cinar, Elif
    Cakmakli, Gul Yalcin
    Te, Banu Cahide
    TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (04) : 189 - 197